Blar i forfatter Det helsevitenskapelige fakultet "Bouscambert, Maude"

Viser treff 1-1 av 1

    • Efficacy and safety of baricitinib in hospitalized adults with severe or critical COVID‑19 (Bari‑SolidAct): a randomised, double‑blind, placebo‑controlled phase 3 trial 

      Trøseid, Marius; Arribas, José R.; Assoumou, Lambert; Holten, Aleksander Rygh; Poissy, Julien; Terzic, Vida; Mazzaferri, Fulvia; Baño, Jesús Rodríguez; Eustace, Joe; Hites, Maya; Joannidis, Michael; Paiva, José-Artur; Reuter, Jean; Püntmann, Isabel; Patrick-Brown, Thale Dawn; Westerheim, Elin; Nezvalova-Henriksen, Katerina; Beniguel, Lydie; Dahl, Tuva Børresdatter; Bouscambert, Maude; Halanova, Monika; Péterfi, Zoltán; Tsiodras, Sotirios; Rezek, Michael; Briel, Matthias; Ünal, Serhat; Schlegel, Martin; Ader, Florence; Lacombe, Karine; Amdal, Cecilie Delphin; Rodrigues, Serge; Tonby, Kristian; Gaudet, Alexandre; Heggelund, Lars; Mootien, Joy; Johannessen, Asgeir; Møller, Jannicke Horjen; Pollan, Beatriz Diaz; Tveita, Anders Aune; Kildal, Anders Benjamin; Richard, Jean-Christophe; Dalgard, Olav; Simensen, Victoria Charlotte; Baldé, Aliou; de Gastines, Lucie; del Álamo, Marta; Aydin, Burç; Lund-Johansen, Fridtjof; Trabaud, Mary-Anne; Diallo, Alpha; Halvorsen, Bente; Røttingen, John-Arne; Tacconelli, Evelina; Yazdanpanah, Yazdan; Olsen, Inge Christoffer; Costagliola, Dominique; Study Group, EU-SolidAct (Journal article; Tidsskriftartikkel; Peer reviewed, 2023-01-10)
      Background Baricitinib has shown efcacy in hospitalized patients with COVID-19, but no placebo-controlled trials have focused specifcally on severe/critical COVID, including vaccinated participants.<p> <p>Methods Bari-SolidAct is a phase-3, multicentre, randomised, double-blind, placebo-controlled trial, enrolling participants from June 3, 2021 to March 7, 2022, stopped prematurely for external ...